Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.

Maksymetz, James; Moran, Sean P; Conn, P Jeffrey

Maksymetz, James; Moran, Sean P; Conn, P Jeffrey.

Affiliation

Maksymetz J; Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA.
Moran SP; Vanderbilt Center for Neuroscience Drug Discovery, Nashville, TN, 37232, USA.
Conn PJ; Vanderbilt Center for Neuroscience Drug Discovery, Nashville, TN, 37232, USA.

Mol Brain ; 10(1): 15, 2017 04 26.

Article in En | MEDLINE | ID: mdl-28446243

Subject(s)

Molecular Targeted Therapy; Receptors, Metabotropic Glutamate/metabolism; Schizophrenia/drug therapy; Schizophrenia/metabolism; Animals; Humans; Models, Biological

Key words

Allosteric modulator; Glutamate; Heterodimer; NAM; PAM; Schizophrenia; Signal bias; mGlu receptor

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Receptors, Metabotropic Glutamate / Molecular Targeted Therapy Limits: Animals / Humans Language: En Journal: Mol Brain Journal subject: BIOLOGIA MOLECULAR / CEREBRO Year: 2017 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google